Elipovimab

• CAT Number: I041523
• CAS Number: 2101210-43-7
• Purity: ≥95%

Elipovimab（Cat No.:I041523）is an investigational monoclonal antibody designed to target the SARS-CoV-2 spike protein, aiming to neutralize the virus and prevent COVID-19 infection. By binding to the spike protein, elipovimab blocks the virus from entering human cells, thus potentially reducing the severity of the disease. It is being studied as a treatment option for individuals with COVID-19, especially those at high risk of severe outcomes. As part of ongoing efforts to combat the pandemic, elipovimab represents an antibody-based therapeutic approach alongside vaccines and other treatments for COVID-19.